Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway
- PMID: 32976685
- PMCID: PMC7643645
- DOI: 10.1002/cam4.3432
Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway
Abstract
Background: Breast cancer is the leading cause of death among women with malignant tumors worldwide. Bone metastasis is the main factor affecting the prognosis of breast cancer. Therefore, both antitumor and anti-breast-cancer-induced osteolysis agents are urgently needed.
Methods: We examined the effect of Asperolide A (AA), a marine-derived agent, on osteolysis and RANKL-induced phosphoinositide 3-kinase (PI3K)/AKT/mTOR/c-FOS/nuclear factor-activated T cell 1 (NFATc1) pathway activation, F-actin ring formation, and reactive oxygen species (ROS) generation in vitro. We evaluated AA effect on breast cancer MDA-MB-231 and MDA-MB-436 cells in vitro through CCK8 assay, wound healing assay, transwell assay, Annexin V-FITC/PI staining for cell apoptosis, and cell cycle assay. Furthermore, we assessed the effect of AA in vivo using a breast cancer-induced bone osteolysis nude mouse model, followed by micro-computed tomography, tartrate-resistant acid phosphatase staining, and hematoxylin and eosin staining.
Results: Asperolide A inhibited osteoclast formation and differentiation, bone resorption, F-actin belt formation, ROS activity, and osteoclast-specific gene and protein expressions and prevented PI3K/AKT/mTOR/c-FOS/NFATc1 signaling activation in a dose-dependent manner in vitro. AA also inhibited breast cancer growth and breast cancer-induced bone osteolysis by reducing osteoclast formation and function and inactivated PI3K/AKT/mTOR signaling in vivo.
Conclusions: Our study demonstrated that AA suppressed bone metastatic breast cancer. These findings indicate AA as a potential, novel curative drug candidate for patients with bone metastatic breast cancer.
Keywords: Asperolide A; bone metastases; breast cancer; mTOR; osteoclast.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
There is no conflict of interest.
Figures
Similar articles
-
Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.Chem Biol Interact. 2024 May 1;394:110968. doi: 10.1016/j.cbi.2024.110968. Epub 2024 Mar 24. Chem Biol Interact. 2024. PMID: 38522564
-
Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.Biol Pharm Bull. 2015;38(1):66-74. doi: 10.1248/bpb.b14-00567. Biol Pharm Bull. 2015. PMID: 25744460
-
Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis.Cancer Lett. 2019 Feb 28;443:135-144. doi: 10.1016/j.canlet.2018.11.038. Epub 2018 Dec 9. Cancer Lett. 2019. PMID: 30540926
-
Breast cancer metastasis to the bone: mechanisms of bone loss.Breast Cancer Res. 2010;12(6):215. doi: 10.1186/bcr2781. Epub 2010 Dec 16. Breast Cancer Res. 2010. PMID: 21176175 Free PMC article. Review.
-
Function of selected natural antidiabetic compounds with potential against cancer via modulation of the PI3K/AKT/mTOR cascade.Biomed Pharmacother. 2021 Dec;144:112138. doi: 10.1016/j.biopha.2021.112138. Epub 2021 Nov 5. Biomed Pharmacother. 2021. PMID: 34750026 Review.
Cited by
-
AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review.Cancers (Basel). 2021 May 11;13(10):2287. doi: 10.3390/cancers13102287. Cancers (Basel). 2021. PMID: 34064589 Free PMC article. Review.
-
The Signaling Pathways Associated With Breast Cancer Bone Metastasis.Front Oncol. 2022 Mar 10;12:855609. doi: 10.3389/fonc.2022.855609. eCollection 2022. Front Oncol. 2022. PMID: 35372035 Free PMC article. Review.
-
Circular RNAs: Their Role in the Pathogenesis and Orchestration of Breast Cancer.Front Cell Dev Biol. 2021 Mar 11;9:647736. doi: 10.3389/fcell.2021.647736. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33777954 Free PMC article. Review.
-
Quercetin as a multi-targeted therapeutic agent in breast cancer: molecular targets and therapeutic potential.Med Oncol. 2025 Jul 22;42(8):365. doi: 10.1007/s12032-025-02907-x. Med Oncol. 2025. PMID: 40694163 Review.
-
Asperolide A induces apoptosis and cell cycle arrest of human hepatoma cells with p53-Y220C mutant through p38 mediating phosphorylation of p53 (S33).Heliyon. 2023 Feb 26;9(3):e13843. doi: 10.1016/j.heliyon.2023.e13843. eCollection 2023 Mar. Heliyon. 2023. PMID: 36923828 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394‐424. - PubMed
-
- Osuala KO, Ji K, Mattingly RR, Sloane BF. Breast cancer: proteolysis and migration. Adv Exp Med Biol. 2019;1152:401‐411. - PubMed
-
- Castaneda SA, Strasser J. Updates in the treatment of breast cancer with radiotherapy. Surg Oncol Clin N Am. 2017;26:371‐382. - PubMed
-
- DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52‐62. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
